Lupin Ltd — Capital/Financing Update 2024

Dec 30, 2024

December 30, 2024

==> picture [84 x 99] intentionally omitted <==

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards acquisition of Huminsulin[®] in India from Eli Lilly and Company to further enhance its diabetes portfolio.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Digitally signed by Amit Kumar Gupta DN: c=IN, o=Personal, title=7875, pseudonym=d30e6db65d0a41f2b9a52198e 78bf149, 2.5.4.20=b7e8678b2d6b381cb8f4761d9cbb 4338253df2c8e93e8fcf768f8e86438a00a1, postalCode=400705, st=Maharashtra, serialNumber=de9bbd80d8994e4be9f0dd2 399144eba7e782d70287df6aad1994f0b522 fa08a, cn=Amit Kumar Gupta Date: 2024.12.30 18:35:16 +05'30'

78bf149, Amit Kumar 2.5.4.20=b7e8678b2d6b381cb8f4761d9cbb 4338253df2c8e93e8fcf768f8e86438a00a1, postalCode=400705, st=Maharashtra, serialNumber=de9bbd80d8994e4be9f0dd2 Gupta 399144eba7e782d70287df6aad1994f0b522 fa08a, cn=Amit Kumar Gupta Date: 2024.12.30 18:35:16 +05'30' AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)

Encl: a/a.

LUPIN LIMITED

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin Acquires Huminsulin from Lilly to Enhance Diabetes Portfolio

Mumbai, December 30, 2024 : Global pharma major Lupin Limited (Lupin) announced today the acquisition of Huminsulin® in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.

The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin Human is prescribed for management along with other concomitant therapies.

“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide highquality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” said Nilesh Gupta, Managing Director, Lupin .

Commenting on the acquisition, Rajeev Sibal, President – India Region Formulations , Lupin said, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

For further information or queries please contact: Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin rajalakshmiazariah@lupin.com